We are live on
!
Find out more
Arbutus Biopharma
ABUS
ABUS
167 hedge funds and large institutions have $626M invested in Arbutus Biopharma in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 48 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
7.72% more ownership
Funds ownership: 63.45% → 71.16% (+7.7%)
7% more capital invested
Capital invested by funds: $587M → $626M (+$39M)
0% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 48
3% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 30
3% less funds holding
Funds holding: 172 → 167 (-5)
20% less call options, than puts
Call options by funds: $2.67M | Put options by funds: $3.34M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
167
Holders Change
-5
Holders Change %
-2.91%
% of All Funds
2.06%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
29
Increased
48
Reduced
48
Closed
30
Calls
$2.67M
Puts
$3.34M
Net Calls
-$671K
Net Calls Change
-$10.2M
Top Buyers
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$26.1M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$22.1M |
| 3 |
Barclays
London,
United Kingdom
|
+$17.3M |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$9.96M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$8.28M |
Top Sellers
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$9.98M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.32M |
| 3 |
SC
Stempoint Capital
New York
|
-$4.75M |
| 4 |
Morgan Stanley
New York
|
-$3.55M |
| 5 |
SCM
Saba Capital Management
New York
|
-$1.67M |
